Most Read Articles
5 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 5 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
6 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.

JAK inhibitors for immune-mediated diseases may increase herpes zoster risk

21 May 2020

The use of Janus kinase (JAK) inhibitors for the treatment of inflammatory bowel diseases (IBDs) and other immune-mediated diseases may increase the risk of herpes zoster infection, reports a recent meta-analysis.

Accessing the databases of the Cochrane Central Register of Controlled Trials, Embase and Medline, researchers retrieved 82 studies corresponding to 66,159 patients with immune-mediated diseases. Most of the enrolled papers were randomized controlled trials. The primary study outcome was the incidence of adverse events.

Forty-four studies investigated the effect of treatment on herpes zoster infection risk, most of which used tofacitinib (n=26), though there were also reports on baricitinib, filgotinib and upadacitinib. In the pooled sample of 48,093 patients, the incidence rate of herpes zoster was 2.11 per 100 patient-years. Among treated comparators, the corresponding rate was 1.23 per 100 patient-years.

This resulted in a significant excess in risk estimate (risk ratio [RR], 1.57, 95 percent CI, 1.04–2.37), which persisted even when limiting analysis to placebo-controlled studies (RR, 1.72, 95 percent CI, 1.07–2.76). Heterogeneity was insignificant.

No such differences in risk were found for other adverse outcomes, including serious infections, malignancies and major cardiovascular events. Mortality was likewise comparable among treatment groups (RR, 0.72, 95 percent CI, 0.40–1.28).

“More studies with long follow-up and in the real-world setting in the different conditions will be needed to fully elucidate the safety profile of the different JAK inhibitors,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.
Jairia Dela Cruz, 16 Sep 2020
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Pearl Toh, 5 days ago
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
6 days ago
Women with pre-eclampsia are at higher risk of developing heart failure, a study suggests.